Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in France / NCT07727369
Starting soon Not applicable

RePer-AGE: Reorganization of Visuo-cognitive Functions Based on Peripheral Vision With Aging

NCT07727369 · tracked via the Priya Life Science France tracker
Sponsor
University Hospital, Grenoble
Phase
Not applicable
Started
2026-09-01
Last updated
2026-07-27

Condition(s) studied

AgingVisual PerceptionCognition

Investigational drug(s) / intervention(s)

Psychophysical visual recognition tasksOphthalmological assessmentFunctional magnetic resonance imaging (fMRI)

Psychophysical visual recognition tasks: Computerized visual recognition tasks assessing the respective contributions of central and peripheral vision to scene recognition and predictive visual processing.

Ophthalmological assessment: Ophthalmological examinations including retinal sensitivity (Humphrey automated perimetry) and low-luminance visual acuity.

Functional magnetic resonance imaging (fMRI): Functional MRI performed during psychophysical visual recognition tasks to assess brain activity associated with visual recognition and predictive visual processing.

Study summary

The RePer-AGE study investigates how central and peripheral vision contribute to visual recognition and how these mechanisms change with normal aging. The study is based on the hypothesis that peripheral vision provides rapid global information that supports visual recognition through predictive mechanisms. Healthy young adults (18-30 years) and older adults (60-85 years) will undergo visual psychophysical testing, ophthalmological examinations, and, for a subset of participants, functional magnetic resonance imaging (fMRI). The results are expected to improve our understanding of age-related changes in visuo-cognitive functions and provide reference data for future studies on age-related visual disorders.

Eligibility

Sex
ALL
Min age
18 Years
Max age
85 Years
Healthy volunteers
Accepted
Inclusion Criteria: * Healthy young adults aged 18 to 30 years or healthy older adults aged 60 to 85 years. * Normal or corrected-to-normal visual acuity. * No ophthalmological disease affecting visual function. * For participants aged 60 years or older: Mini-Mental State Examination (MMSE) score ≥23. * Affiliated with a national health insurance system. * Written informed consent. Non inclusion Criteria: * Individuals protected under French regulations governing research involving human participants. * Employees or individuals under the direct authority of the investigators. * History of neurological or psychiatric disorders likely to affect visual or cognitive functions. * Current treatment likely to alter visual function or vigilance. * MRI contraindications (metallic implants, pacemaker, severe claustrophobia, or other MRI safety contraindications) for participation in the MRI arm only.

Primary outcome measure(s)

  • Behavioral performance during scene categorization tasks — Baseline (single experimental session)
    Behavioral performance will be assessed using accuracy and response time during computerized scene categorization tasks evaluating (1) central versus peripheral vision (EXC paradigm) and (2) semantic congruency between peripheral and central vision (VPC paradigm). Comparisons will be performed between young and older adults.

Trial sites (1)

FacilityCityRegionStatus
CHU Grenoble Alpes Grenoble Isère

More University Hospital, Grenoble trials in France

Machine Learning Assisted Electrochemical Profiling to Provide Early Identification of Bloodstream Infections Pathogens Recruiting
Tumor Immune Microenvironment Involvement in Colorectal Cancer Chemoresistance Mechanisms Recruiting
City-Hospital Collaboration for Early Detection of Liver Fibrosis in Primary Care: A Secondary Prevention Project in the Grenoble Health Area Recruiting
Tool for Evaluating the Effectiveness of the DENVER Protocol Starting soon
Evaluation of Deep Brain Stimulation (DBS) of the Right Operculum 3 (OP3) in Permanent Non-pulsatile Disabling Tinnitus (TINNOP3-DBS) Recruiting

Other trials for the same condition

Research on the Evolution, Geometry, and Alterations of the Periorbital Region Based on Age and Deformations Active, not recruiting
Links Between Cognitive Deficits During Normal or Pathological Aging and Slow Waves Measured in EEG Recruiting
Biobank and Brain Health in Bordeaux. Recruiting
Evolution of the Relationship Between Central and Peripheral Arterial Wave Velocities as a Function of Age Starting soon
Aging Well Together - 'Getting to Know You Better': Characterization of Health FACTors in People Advancing in AGE Starting soon
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07727369 on ClinicalTrials.gov ↗ ← All trials in France